44 results about "Instilling eye drops" patented technology

The invention relates to the field of biological medicine, in particular to a carrier-free nanoparticle which is formed by self-assembly of cyclosporine A and costunolide through intermolecular weak interaction. The invention also provides a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of medicines for treating xerophthalmia. The carrier-free nano eye drops based on the synergistic effect of Chinese and western medicines are used for anti-inflammatory treatment of the xerophthalmia, a new strategy is provided for precise diagnosis and treatment of the xerophthalmia, the problems of single target spot, limited curative effect and the like in traditional treatment are solved, and more efficient inflammation control is expected to be achieved. While the curative effect is improved, the tolerance risk caused by long-term use is reduced, double optimization of the curative effect and safety is realized, and the limitation of traditional single drug treatment is broken through. By adopting the carrier-free nano preparation, the delivery efficiency of the medicine on the ocular surface is effectively improved, the bioavailability is enhanced, powerful support is provided for improving the curative effect of the medicine, and the carrier limitation bottleneck is broken through.

The invention relates to the technical field of pharmaceutical preparations, and provides double-shell JAK inhibitor nanoparticles, a preparation method thereof and targeted delivery eye drops. The double-shell JAK inhibitor nanoparticle provided by the invention comprises a core, an inner shell and an outer shell, wherein the core comprises a nanostructure lipid carrier and a JAK inhibitor; the inner shell layer is a cationic polymer, and the outer shell layer is hyaluronic acid. Through the design of the positive charge inner shell layer and the negative charge outer shell layer, the dual functions of mucosa adhesion and active targeting are achieved, the surface of the nanoparticle is electronegative finally, cytotoxicity possibly caused by direct exposure of a cationic polymer is reduced, non-specific aggregation of the cationic polymer and electronegative protein in tears is avoided, and the stability of tears is improved. And the stability of the preparation is improved. The eye drops provided by the invention can obviously prolong the residence time of the JAK inhibitor on the ocular surface, enhance the cornea permeability, can actively target to ocular inflammatory cells, and have a wide application prospect.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a cromolyn sodium eye drop without antioxidant. The cromolyn sodium eye drop comprises cromolyn sodium liposome and pharmaceutically acceptable additives; a formula is preferred in the preparation process of the cromolyn sodium liposome, so that the cromolyn sodium liposome has a high drug loading and encapsulation efficiency, and lays a foundation for further preparation into a preparation. In addition, the cromolyn sodium liposome eye drop of the application does not add antioxidant, and also has high stability, and is qualified in a sterile test and has high light stability.

The invention relates to a preparation method of brimonidine tartrate eye drops, particularly relates to a new technical scheme obtained by adjusting the rotating speed, the temperature and the material adding sequence, and solves the problems of non-uniform content of benzalkonium chloride and dissolution of polyvinyl alcohol. The brimonidine tartrate eye drops prepared by the preparation method disclosed by the invention are uniform in benzalkonium chloride content, clear in liquid medicine, stable in quality, low in requirements on production equipment and suitable for large-scale industrial production.

The invention relates to the technical field of medical analysis, in particular to a method for detecting the content of an antioxidant in bromfenac sodium eye drops through liquid chromatography, and particularly relates to a method for detecting the content of the antioxidant anhydrous sodium sulfite of the bromfenac sodium eye drops through high performance liquid chromatography. Wherein the mobile phase A is a methanol-buffer salt solution; a mobile phase B is methanol; eluting by using a gradient mobile phase, wherein the volume ratio of the mobile phase is 100%; preparing a reference solution and a test solution by taking the mobile phase A as a diluent, then respectively injecting the reference solution and the test solution into a liquid chromatograph, and recording chromatograms; calculating the content of anhydrous sodium sulfite by adopting an external standard method; the method comprises the following specific steps: (1) preparation of a reference substance solution: taking an anhydrous sodium sulfite reference substance, and adding a diluent for dissolving to obtain the reference substance solution; and (2) preparation of a test solution: taking the bromfenac sodium eye drops, and adding a diluent to dilute the bromfenac sodium eye drops to obtain the bromfenac sodium eye drops. The method disclosed by the invention is strong in specificity, high in stability, high in precision and high in accuracy, and has practical significance on quality control of the bromfenac sodium eye drops.

The invention relates to a method for determining the content of tobramycin in tobramycin eye drops, which comprises the following steps: 1) preparation of a reference substance solution: taking a tobramycin reference substance, and adding water and sulfuric acid to dissolve the tobramycin reference substance to prepare the reference substance solution; 2) preparation of a test solution: diluting tobramycin eye drops with water to prepare a reference solution; 3) preparation of derivatization solutions: respectively adding the reference substance solution and the test substance solution into a 2, 4-dinitrofluorophenethyl alcohol solution and a tris (hydroxymethyl) aminomethane solution for reaction, and adding acetonitrile after the reaction is completed to prepare a reference substance derivatization solution and a test substance derivatization solution; and 4) determination: taking the reference substance derivatization solution and the test sample derivatization solution, respectively injecting into a high performance liquid chromatograph to obtain chromatograms, and calculating the tobramycin content by using an external standard method according to the peak area of the chromatograms.

The invention relates to a drug sustained release system, in particular to lipid liquid crystal precursor eye drops as well as a preparation method and application thereof. The lipid liquid crystal precursor eye drops comprise a matrix material, a cosolvent and a raw material medicine, wherein the matrix material is an amphiphilic substance and an oil phase; the lipid liquid crystal precursor eye drops are prepared from the following components in percentage by weight: 0 to 35 percent of amphiphilic substance, 40 to 80 percent of oil phase, 15 to 20 percent of cosolvent and 0.001 to 5 percent of raw material medicine. According to the constructed drug-loaded lipid liquid crystal precursor eye drops, when the drug-loaded lipid liquid crystal precursor makes contact with water in tears, the drug-loaded lipid liquid crystal precursor can instantly become drug-loaded lipid liquid crystal gel, compared with common eye drops, the retention time of the drug-loaded lipid liquid crystal gel on the ocular surface is longer, the lipid liquid crystal has a phospholipid bilayer structure, and the drug-loaded lipid liquid crystal gel can be used for preparing the drug-loaded lipid liquid crystal precursor eye drops. Insoluble raw material medicines can be distributed in the lipid layer, so that the solubility of the raw material medicines is greatly improved, the raw material medicines can be slowly released by gelatinizing after meeting water, the administration frequency is reduced, the bioavailability and patient compliance are greatly improved, and the defects of the eye drops in treatment of glaucoma are overcome.

The invention designs a new application of grape seed procyanidine in prevention and treatment of cataract. The method comprises the following steps: constructing a cataract injury model by inducing rabbit crystalline lens oxidative injury with hydrogen peroxide, culturing by adopting a domestic rabbit crystalline lens, detecting the activity of total superoxide dismutase, glutathione peroxidase and catalase and the content of malondialdehyde by observing the opacity and structural form of the crystalline lens, and detecting the expression of apoptosis regulation proteins BCL-2 and BAX in combination with immunohistochemistry. And the protective effect and molecular mechanism of the grape seed procyanidine on crystalline lens injury are researched. Researches show that the grape seed procyanidine has a protective effect on hydrogen peroxide induced rabbit crystalline lens injury, and the mechanism of the grape seed procyanidine is related to an antioxidant effect and adjustment of BCL-2 / BAX apoptotic protein; rabbit eye stimulation experiments prove that the grape seed procyanidine has no stimulation or only slight stimulation to rabbit eyes. Therefore, the grape seed procyanidine can prevent cataract, is a potential cataract treatment medicine, provides a new way for development of related medical products such as eye drops, and has good clinical application value.

The invention provides oxygen-enriched eye drops based on oxygen-containing lipidosome and application of the oxygen-enriched eye drops. The preparation method comprises the following steps: firstly, preparing blank liposome powder through a film dispersion-freeze drying technology, carrying out oxygenation treatment on the blank liposome powder to prepare oxygen-containing liposome, and then mixing the oxygen-containing liposome with sodium hyaluronate eye drops to obtain the oxygen-enriched eye drops. According to the oxygen-enriched eye drops, the permeability of oxygen in corneal tissues is improved, proliferation of corneal epithelial cells is remarkably promoted, and the apoptosis process of the corneal epithelial cells is delayed. The oxygen-enriched eye drops can promote repair after corneal epithelium injury.

The application discloses a kind of zinc sulfide nanometer eye drops and its preparation method and application, the zinc sulfide nanometer eye drops includes zinc sulfide nanoparticles and sterile water, the zinc sulfide nanoparticles are spherical nanoparticles with pseudo-virus-like spike structure, and particle size is 150-250nm, and the zinc sulfide nanoparticles can release hydrogen sulfide gas under eye acidic inflammatory microenvironment.The application can realize the stable, slow, controllable release of hydrogen sulfide gas under eye acidic inflammatory microenvironment, utilize the anti-inflammatory, antioxidant, promote mucosa repair and improve tear film stability and other biological functions of gas signal molecule hydrogen sulfide, realize the effective treatment of dry eye, relieve eye dryness, inflammation, injury and other symptoms;The formula of the application is mild, has no obvious cytotoxicity and eye irritation, has good biological safety, can meet the needs of long-term, safe and comfortable use in clinic, provides a new, efficient and safe gas treatment approach for dry eye.

The application provides a kind of eye drop composition and its preparation method and application, belong to ophthalmic preparation technical field.The eye drop composition used in the application includes the following components: brimonidine tartrate, hyaluronic acid, collagen, trehalose, injection water;By compounding each component, a kind of eye drop capable of realizing brimonidine tartrate sustained release, prolonging the time of antihypertensive effect, and having the characteristics of reducing blinking discomfort, long-acting moisturizing, anti-inflammatory soothing, mild antiseptic, etc. is prepared;The eye drop of the application is helpful to glaucoma, high eye pressure, dry eye, postoperative inflammation or allergy, preservative-sensitive or preservative-allergic population, improves the quality of life, relieves the disease.

The invention belongs to the technical field of medicine. The invention relates to the field of eye drops, in particular to application of ipratropium bromide in the aspect of preventing or improving myopia and eye drops containing ipratropium bromide. The research proves that the single drug of the ipratropium bromide can effectively inhibit the growth of the ocular axis and the deterioration of the diopter, and the brand new medicinal value of the ipratropium bromide in the aspect of preventing and improving the myopia is disclosed for the first time. More importantly, the invention finds that the combination of the ipratropium bromide and the diquafosol sodium can generate a remarkable synergistic effect, and the curative effect of the combined preparation is far better than that of a single drug and even better than that of a clinical drug atropine. The invention provides a safe, effective and long-term brand new drug choice for myopia prevention and control, and has good application prospect and value.

The present invention provides a method for treating an ocular disorder in a subject in need thereof, comprising topically administering a therapeutically effective amount of a TRPM8 agonist to surfaces of ocular margin of the subject, wherein the ocular margin is the primary target site for delivery of the TRPM8 agonist. The method may use a wiping, brushing, or spraying approach, and is more effective and efficient than the conventional method using eye drops.

The present application relates to a kind of dry eye drops, it includes by mass percentage: chondroitin sulfate 0.1%-0.5%, silk fibroin nanoparticles containing astaxanthin 0.06%-0.3%, sodium hyaluronate 0.1%-0.3%, vitamin E 0.05%-0.1%, sodium chloride 0.9-1.0%, poloxamer 0.05%-0.1%, EDTA 0.01%-0.1%, phosphate buffer and the balance of water;Wherein, the silk fibroin nanoparticles containing astaxanthin particle size is 50-300nm;Phosphate buffer is adjusted to 6.8-7.9 to the pH of eye drop.The eye drop of the present application can effectively relieve dry eye symptoms, provide long time wet and protection, while reducing eye inflammation and oxidative stress, significantly improve dry eye, and high use safety.

This invention relates to a small molecule compound composition and its applications, belonging to the field of biotechnology. The small molecule compound composition of this invention includes NU7441, GW9662, and D609, or their stereoisomers. This invention is the first to discover that this small molecule compound combination can effectively inhibit oxidative damage to corneal epithelial cells caused by hyperosmolarity and significantly improve the survival rate of corneal epithelial cells. In vivo animal experiments show that, compared with the control group, the experimental group of mice injected with scopolamine-induced dry eye model mice, given eye drops containing the small molecule compound combination, showed significantly reduced corneal defects and increased tear secretion. The small molecule compound combination can effectively prevent corneal epithelial damage, has high efficacy, and no obvious drug toxicity. This small molecule compound combination may become a potent and effective drug for the clinical treatment of dry eye in the future.

The application discloses a new use of 4F dimer polypeptide and lipids thereof, and the 4F dimer polypeptide and lipids thereof are used for preparing a drug for treating dry eye syndrome. The application has the advantages that the application innovatively finds that pHDL has very good effects on dry eye syndrome, and has the advantages of synergistic treatment for the multi-factor pathological mechanism of dry eye syndrome. Therefore, compared with the existing single mechanism drug (such as cyclosporine eye drops for only inhibiting inflammation), the multi-dimensional action mechanism of pHDL precisely matches the complex pathological network of dry eye syndrome, and is expected to improve the coverage range of the curative effect on refractory dry eye syndrome.

The invention relates to chitosan nanogel sustained-release anti-inflammatory eye drops and a preparation method thereof. The eye drops are mainly prepared from nanogel which is constructed by double modified chitosan and 2-hydroxyethyl-3-methoxypropionamide in a synergistic manner. The mucous membrane adhesiveness of the chitosan and the stability of the nanogel are improved through double modification of amino-polyphenol in-situ oxidation crosslinking and phosphate esterification. Due to the introduction of small molecule 2-hydroxyethyl-3-methoxyl propionamide, the particle size uniformity of the nanogel and the slow release performance of the medicine are improved. The eye drops have excellent adhesiveness, stability and slow release performance, can significantly prolong the residence time of drugs on the ocular surface and reduce the administration frequency, and have good storage stability. Through contrast experiments, the eye drops disclosed by the invention are superior to a single modified system in the prior art in the aspects of particle size distribution, slow release property, adhesiveness and stability, and have great clinical application potential.

This invention belongs to the technical field of biomedicine and discloses the application of a composition comprising neo-agar oligosaccharides and astaxanthin in the preparation of formulations for the treatment of dry eye syndrome, as well as the formulation of in-situ gel eye drops and its preparation method. The composition provided by this invention specifically comprises neo-agar oligosaccharides and astaxanthin, which together constitute an organic whole, synergistically contributing to excellent ocular surface retention time and penetration efficiency. It can effectively inhibit the activation of core inflammatory pathways at low doses, reduce inflammatory cell infiltration in ocular surface tissues, promote goblet cell proliferation and epithelial repair, increase tear secretion, and improve corneal epithelial integrity. This achieves multiple effects, including anti-inflammatory properties, increased tear secretion, reduced corneal damage, promotion of ocular surface tissue repair, and improvement of corneal epithelial integrity. Furthermore, the composition exhibits excellent ocular surface biocompatibility and has very promising application prospects in the preparation of formulations for the treatment of dry eye syndrome.

Provided are an artemisinin derivative and a preparation method and use thereof. A structural formula of the artemisinin derivative is shown in Formula I. The compound has suitable solubility and is relatively stable under storage conditions. Pharmacokinetic experiments on the compound have shown that artemisinin is detectable in ocular tissues and is present in cornea, conjunctiva, and aqueous humor at a relatively high drug concentration. The compound is therefore an excellent precursor to artemisinin. The compound shown in Formula I exhibits remarkable absorbability, and the drug concentration in the ocular tissues indicates that the compound is well absorbed. The compound exhibits significantly better inhibitory effects on neovascularization in burn models than artemisinin, and can be prepared into liquid formulations such as eye drops, injection, etc., for treatment of ocular tissue diseases.

A novel humectant eye drop composition is disclosed. The composition comprises a synergistic combination of nicotinamide and adenosine in concentrations at which neither component is effective individually. In preferred embodiments of the invention, the composition comprises 0.025% (w / v) and 0.05% (w / v) nicotinamide. Within 2 - 3 weeks of commencement of application, the composition improves the Tear Film Breakup Time, improves tear production as measured by the Schirmer Test, reduces the severity of the Dry Eye Syndrome as measured by Lissamine Green staining, and shows anti-inflammatory effects.

The application discloses a method for establishing an angle-closure glaucoma animal model. The method comprises the following steps: performing mydriasis on an eye of an animal model after general anesthesia, performing local anesthesia on an eye surface of the model eye after 10 minutes; after the pupil of the model eye is reduced, eye gel is added to the eye surface; a semiconductor laser is used to uniformly hit a plurality of laser points at an iris margin; and eye drops are added to the eye surface after laser treatment. The method uses a 532nm laser to hit the iris margin, causes local edema of the iris margin, narrows a passage through which aqueous humor flows from the posterior chamber into the anterior chamber, and increases the pressure of the posterior chamber. The method can keep the high intraocular pressure of the established angle-closure glaucoma animal model between 20-30mmHg, the success rate is 70%, the high intraocular pressure can be maintained for more than one week, no wound is caused on the eye of the animal model, there is no inflammatory reaction on the eye surface, the cornea has no edema and new blood vessels, and the operation of the model can be completed within 10 minutes.

The application provides an application of alpha-ketoglutaric acid in improving corneal endothelial injury and dysfunction, and belongs to the technical field of biological medicine. The application finds that, as a key metabolic intermediate in the tricarboxylic acid cycle, alpha-ketoglutaric acid can significantly reduce corneal endothelial cell injury and dysfunction induced by various causes such as high glucose, genetic defects, high intraocular pressure and surgical trauma by improving mitochondrial energy metabolism, reducing oxidative stress, stabilizing mitochondrial structure and membrane potential. Experiments prove that alpha-ketoglutaric acid can be used in the form of local administration such as eye drops, anterior chamber perfusion, systemic oral administration or combined administration, effectively reduces corneal edema, reduces central corneal thickness, shortens the recovery time of corneal transparency, and has a clear protection and repair effect on diabetic-related corneal endothelial lesions, Fuchs corneal endothelial dystrophy, glaucoma high intraocular pressure injury and intraocular surgery-related endothelial injury.

The invention discloses a culture method and application of umbilical cord mesenchymal stem cells, mainly relates to the technical field of mesenchymal stem cells, and aims at solving the technical problem of obtaining umbilical cord mesenchymal stem cell exosomes with higher purity through culture and improving the cell survival rate after resuscitation. Compared with the prior art, the purification auxiliary agent is added in the culture method of the umbilical cord mesenchymal stem cells, the purification auxiliary agent is one or more of polyethylene glycol, sodium chloride and heparin sodium, the precipitation efficiency and separation purity of exosomes are improved, and residues of impurities such as impure protein are reduced; furthermore, an antioxidant is added, the antioxidant is one of ascorbyl palmitate, alpha-tocopherol and glutathione, the survival rate of the exosome after recovery is increased by reducing oxidative damage of the exosome in the treatment process, and finally the obtained high-purity and high-activity exosome is applied to eye drops for treating xerophthalmia.

The invention discloses application of siRNA of silence Ier3 gene in preparation of medicine for preventing or treating meibomian gland dysfunction type dry eye, Ier3 gene expression is regulated and controlled through RNA interference technology, and meibomian gland dysfunction in plateau environment is relieved. The invention discovers that the expression of the early response gene Ier3 in hypoxia-induced meibomian gland dysfunction is up-regulated for the first time, and designs and synthesizes three specific siRNA sequences. Experiments adopt a low-pressure oxygen chamber to simulate an altitude of 5000 meters to construct a plateau mouse model, intervention is performed through an eye drop administration mode, and results show that Ier3 siRNA can significantly inhibit meibomian gland tissue Ier3 expression, prolong tear film rupture time and inhibit meibomian gland duct cell proliferation. The invention provides a precise treatment strategy based on the RNA interference technology, has the characteristics of strong targeting property, high gene silencing efficiency and small side effect, and provides a new intervention target and drug selection for the treatment of the plateau environment related meibomian gland dysfunction type dry eye.

The application belongs to the technical field of biological medicine, and particularly discloses a Bradyrhizobium sp. (Lupuli) exosome and application thereof in preparation of a product for treating dry eye syndrome, and provides application of the Bradyrhizobium sp. (Lupuli) exosome in preparation of a product for preventing and / or treating dry eye syndrome. The Bradyrhizobium sp. (Lupuli) exosome provided by the application can inhibit growth of Staphylococcus epidermidis, promote transformation of anti-inflammatory phenotype M2 macrophages, reduce content of M1 macrophage pro-inflammatory factors, and increase content of M2 macrophage anti-inflammatory factors. The Bradyrhizobium sp. (Lupuli) OMV is configured into eye drops and added to an ocular surface in the form of eye drops. It is observed that the Bradyrhizobium sp. (Lupuli) OMV has an improvement effect on dry eye disease phenotype of a dry eye mouse model. Pathological sections and inflammatory factor detection also find that the Bradyrhizobium sp. (Lupuli) OMV reduces inflammatory damage of an eye tissue of a dry eye model mouse. The Bradyrhizobium sp. (Lupuli) OMV provided by the application can significantly improve symptoms and signs of dry eye syndrome.

The invention provides intelligent eye drop medication management equipment. The intelligent eye drop medication management equipment comprises a sleeve and a microprocessor unit, wherein the sleeve is used for accommodating an eye drop bottle; the microprocessor unit is connected with the sleeve, and after an eye drop bottle is inserted into the sleeve, the microprocessor unit identifies the eye drop bottle and establishes data association; the microprocessor unit comprises a gyroscope sensor and is used for detecting the dripping action of the eye drop bottle; the microprocessor unit is configured to recognize medicine dropping actions through the gyroscope sensor, record medicine taking data and send the medicine taking data to a mobile terminal through the communication module. The device is reasonable in design, for a patient, the device is convenient to use, and missed drops and wrong drops are remarkably reduced through the intelligent reminding and automatic recording functions; for doctors, quantifiable compliance data provides an objective basis for clinical decision making, remote patient management is realized, and the device and the method provided by the invention effectively improve the medication compliance of patients with chronic eye diseases such as glaucoma and the like.

The application discloses a kind of drug composition for treating pseudomyopia and preparation method thereof, belong to the field of medicine.The application provides the method that scopolamine is combined with tometilcaine in the preparation of the drug for treating pseudomyopia.A kind of drug composition for treating pseudomyopia is also provided.The scopolamine tometilcaine compound eye drops of the application, active ingredients are extracted from plants and crystallized into salt, prepared into compound eye drops, curative effect is remarkable, side effect is low, process is simple, cost is low, medication, carrying, storage is convenient.

A method of treating a subject having glaucoma comprises performing excimer laser trabeculostomy (ELT) on a subject having glaucoma and having previously undergone a failed treatment or a treatment that has been rendered ineffective by progression of the disease. In some examples, the failed treatment is a non-surgical treatment comprising administering medicated eye drops. In some examples, the failed treatment is a laser treatment or surgical treatment, such as a trabeculoplasty, iridotomy, iridectomy, trabeculectomy, trabeculotomy, goniotomy, surgical insertion of a shunt or implant, deep sclerectomy, viscocanalostomy, or a combination thereof.

In one aspect, the disclosure relates to clearing compounds capable of rendering at least one tissue transparent for a period of time, compositions comprising the same, pendant molecules bonded to the compounds capable of covalently or non-covalently binding to tissue such as collagen mimetic peptide, and macromolecules derivatized with the same. In another aspect, the compositions can be useful in clinic for visualizing internal anatomical structures and / or for clearing opacities of the eye. In one aspect, the compositions are topical, e.g., eye drops, lotions, or creams, or are injectable. In some aspects, an injection is performed directly into opaque tissue such as neural tissue, connective tissue, internal organs, ocular tissue, or the like. In other aspects, the clearing compound is injected adjacent to the target structure. The clearing compounds can be colorless across the entire visible spectrum, are non-toxic, and are excreted by the subject after visualization of tissue structures.